ADMA Biologics Statement on Tariffs
Provided By GlobeNewswire
Last update: Apr 7, 2025
RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
Read more at globenewswire.comNASDAQ:ADMA (4/21/2025, 3:36:08 PM)
19.31
-2 (-9.39%)
Find more stocks in the Stock Screener
ADMA Latest News and Analysis
5 days ago - ChartmillInvestors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
